Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose

OBJECTIVE: To evaluate inactivated CoronaVac prime vaccination, antibody decay, booster dose, and safety in ANCA-Associated Vasculitis (AAV) patients. METHODS: Fifty-three AAV patients and 106 Controls (CG) received CoronaVac on days: D0 (first dose), D28(second dose), and D210 (booster dose, 32 AAV...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Rosa M.R., Dagostin, Marilia A., Caparbo, Valeria F., Sales, Lucas P., Pasoto, Sandra G., Silva, Clovis A., Yuki, Emily F.N., Saad, Carla G.S., Medeiros-Ribeiro, Ana C., Kupa, Leonard V.K., Fusco, Solange R.G., Martins, Victor A.O., Martins, Carolina C.M.F., Barbas, Carmen Valente, Shinjo, Samuel K., Aikawa, Nadia E., Bonfa, Eloisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705212/
https://www.ncbi.nlm.nih.gov/pubmed/36529052
http://dx.doi.org/10.1016/j.clinsp.2022.100150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705212/
https://www.ncbi.nlm.nih.gov/pubmed/36529052
http://dx.doi.org/10.1016/j.clinsp.2022.100150

Ejemplares similares